Cartesian Therapeutics (RNAC) Projected to Announce Quarterly Earnings on Thursday

Cartesian Therapeutics (NASDAQ:RNAC) will likely be announcing its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $0.16 million for the quarter.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its earnings results on Thursday, August 6th. The company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.34. On average, analysts expect Cartesian Therapeutics to post ($3.15) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Cartesian Therapeutics Price Performance

RNAC stock opened at $6.69 on Thursday. Cartesian Therapeutics has a one year low of $5.60 and a one year high of $11.00. The stock has a market cap of $202.37 million, a PE ratio of -1.13 and a beta of 0.65. The firm has a 50 day simple moving average of $7.89 and a two-hundred day simple moving average of $7.67.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cartesian Therapeutics in a research report on Wednesday, September 9th. Wall Street Zen upgraded shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, September 29th. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday, August 18th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, September 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).